JP2008540563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540563A5 JP2008540563A5 JP2008511366A JP2008511366A JP2008540563A5 JP 2008540563 A5 JP2008540563 A5 JP 2008540563A5 JP 2008511366 A JP2008511366 A JP 2008511366A JP 2008511366 A JP2008511366 A JP 2008511366A JP 2008540563 A5 JP2008540563 A5 JP 2008540563A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- nebulizer
- mutated
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 16
- 239000006199 nebulizer Substances 0.000 claims 11
- 210000004072 lung Anatomy 0.000 claims 10
- 239000013543 active substance Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 6
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 claims 5
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 claims 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 5
- 229960000074 biopharmaceutical Drugs 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010059245 Angiopathy Diseases 0.000 claims 3
- 206010006448 Bronchiolitis Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 3
- 108010035532 Collagen Proteins 0.000 claims 3
- 206010014561 Emphysema Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 3
- 239000000443 aerosol Substances 0.000 claims 3
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 201000009267 bronchiectasis Diseases 0.000 claims 3
- 206010006451 bronchitis Diseases 0.000 claims 3
- 229920001436 collagen Polymers 0.000 claims 3
- 230000024203 complement activation Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 229940071648 metered dose inhaler Drugs 0.000 claims 3
- 230000000414 obstructive effect Effects 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 238000002716 delivery method Methods 0.000 claims 2
- 238000012383 pulmonary drug delivery Methods 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 229940126585 therapeutic drug Drugs 0.000 claims 2
- 229940008126 aerosol Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002663 nebulization Methods 0.000 claims 1
- 229950003203 pexelizumab Drugs 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/127,438 US20050271660A1 (en) | 2002-09-06 | 2005-05-11 | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| PCT/US2006/018269 WO2006122257A2 (en) | 2005-05-11 | 2006-05-10 | Nebulization of monoclonal antibodies for treating pulmonary diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012193985A Division JP2012233013A (ja) | 2005-05-11 | 2012-09-04 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540563A JP2008540563A (ja) | 2008-11-20 |
| JP2008540563A5 true JP2008540563A5 (enExample) | 2009-06-04 |
Family
ID=37054603
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511366A Withdrawn JP2008540563A (ja) | 2005-05-11 | 2006-05-10 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
| JP2012193985A Pending JP2012233013A (ja) | 2005-05-11 | 2012-09-04 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
| JP2014125985A Pending JP2014169332A (ja) | 2005-05-11 | 2014-06-19 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012193985A Pending JP2012233013A (ja) | 2005-05-11 | 2012-09-04 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
| JP2014125985A Pending JP2014169332A (ja) | 2005-05-11 | 2014-06-19 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20050271660A1 (enExample) |
| EP (1) | EP1881993A2 (enExample) |
| JP (3) | JP2008540563A (enExample) |
| AU (1) | AU2006243994B2 (enExample) |
| CA (1) | CA2608195A1 (enExample) |
| NZ (2) | NZ582627A (enExample) |
| WO (1) | WO2006122257A2 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271660A1 (en) * | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| EP1545611B1 (en) * | 2002-09-06 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| WO2010081856A1 (en) * | 2009-01-14 | 2010-07-22 | Ablynx Nv | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| BRPI0416654A (pt) * | 2003-11-17 | 2007-01-16 | Nektar Therapeutics | introdução de aerossol a um circuito ventilador |
| DK1713503T3 (da) | 2004-02-10 | 2013-11-04 | Univ Colorado Regents | Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| ES2548700T3 (es) | 2005-05-26 | 2015-10-20 | The Regents Of The University Of Colorado, A Body Corporate | Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas |
| US20070191262A1 (en) * | 2005-11-15 | 2007-08-16 | University Of Iowa Research Foundation | Cancer Therapy and Prevention Based on Modulation of Complement activity |
| DK2359834T5 (en) * | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
| EP2061501B1 (en) * | 2006-09-08 | 2015-04-08 | Volution Immuno Pharmaceuticals SA | Method of treating respiratory disorders |
| US8312879B2 (en) * | 2006-10-16 | 2012-11-20 | General Electric Company | Method and apparatus for airway compensation control |
| AU2008251943B2 (en) | 2007-03-14 | 2013-09-05 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| ES2742268T3 (es) * | 2007-12-26 | 2020-02-13 | Xencor Inc | Variantes de Fc con unión alterada a FcRn |
| CA2718588A1 (en) * | 2008-02-19 | 2009-08-27 | The Trustees Of The University Of Pennsylvania | Complement inhibitors as therapeutic agents for treatment of cancer |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| RS64039B1 (sr) | 2008-11-10 | 2023-04-28 | Alexion Pharma Inc | Metode i kompozicije za lečenje poremećaja povezanih sa komplementom |
| GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| EP2427497B1 (fr) | 2009-05-07 | 2016-12-07 | Stallergenes | Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale |
| KR20100123240A (ko) * | 2009-05-15 | 2010-11-24 | 포항공과대학교 산학협력단 | 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법 |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| AU2010266127B2 (en) | 2009-07-02 | 2015-11-05 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| EP2523976B1 (en) | 2010-01-11 | 2018-04-25 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
| HRP20191071T1 (hr) | 2010-02-11 | 2019-09-20 | Ablynx N.V. | Postupci i pripravci za pripremu aerosola |
| KR101800913B1 (ko) | 2010-04-30 | 2017-12-20 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-c5a 항체들과 이 항체들을 이용하는 방법 |
| EP2585110A4 (en) | 2010-06-22 | 2014-01-22 | Univ Colorado Regents | ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3 |
| US20130164338A1 (en) * | 2010-08-30 | 2013-06-27 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| CA3086367A1 (en) | 2010-09-29 | 2012-04-05 | Pulmatrix Operating Company, Inc. | Monovalent metal cation dry powders for inhalation |
| WO2013126006A1 (en) | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
| TW201400499A (zh) * | 2012-03-12 | 2014-01-01 | Revo Biolog Inc | 抗凝血酶用於治療妊娠毒血症之用途 |
| US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| AR091977A1 (es) | 2012-08-03 | 2015-03-11 | Revo Biolog Inc | El uso de antitrombina en la oxigenacion de membranas extracorporeas |
| EP2912065A4 (en) | 2012-10-25 | 2016-10-19 | True North Therapeutics Inc | ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF |
| RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| US20140170158A1 (en) * | 2012-12-17 | 2014-06-19 | The Johns Hopkins University | Compositions and methods for treating or preventing lung diseases |
| WO2014160958A1 (en) | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| AU2014306002B2 (en) | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| JP7224092B2 (ja) | 2014-04-03 | 2023-02-17 | ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト | 免疫グロブリンの噴霧化 |
| JP6532034B2 (ja) * | 2015-03-24 | 2019-06-19 | 学校法人関西医科大学 | 鼻腔抵抗の測定方法、鼻腔抵抗及び肺気道抵抗の測定方法及び該方法の実施に用いる測定装置 |
| BR112017021289A2 (en) | 2015-04-06 | 2018-06-26 | Bioverativ Usa Inc. | humanized anti-c1s antibodies and methods of use |
| CA2986957A1 (en) | 2015-06-03 | 2016-12-08 | Children's Hospital Medical Center | Compositions and methods for treating neonatal biliary atresia |
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| MY191668A (en) | 2016-06-14 | 2022-07-06 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| EP3525583B8 (en) | 2016-10-12 | 2025-09-10 | Bioverativ USA Inc. | Anti-c1s antibodies and methods of use thereof |
| US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| ES2965486T3 (es) | 2017-07-27 | 2024-04-15 | Alexion Pharma Inc | Formulaciones de anticuerpos anti-C5 de alta concentración |
| KR20200070355A (ko) | 2017-10-26 | 2020-06-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여 |
| JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｃ５抗体組み合わせ物およびその使用 |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| ES2996257T3 (en) | 2018-05-31 | 2025-02-12 | Alexion Pharma Inc | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| WO2020006266A1 (en) | 2018-06-28 | 2020-01-02 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| US12240893B2 (en) | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
| WO2020092546A1 (en) * | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions |
| IL283734B2 (en) | 2018-12-12 | 2025-03-01 | Kite Pharma Inc | Chimeric antigen receptors and CAR-T cells and methods of use |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| BR112022021450A2 (pt) | 2020-04-24 | 2022-12-27 | Millennium Pharm Inc | O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada |
| US20230277524A1 (en) | 2020-05-22 | 2023-09-07 | Trailhead Biosystems Inc. | Combination therapy for treatment of viral infections |
| US12012458B2 (en) | 2020-06-12 | 2024-06-18 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
| CN117425673A (zh) | 2021-04-09 | 2024-01-19 | 武田药品工业株式会社 | 靶向补体因子d的抗体和其用途 |
| KR20240004286A (ko) | 2021-04-26 | 2024-01-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항 Clec12A 항체 및 이의 용도 |
| MX2023011712A (es) | 2021-04-26 | 2023-10-12 | Millennium Pharm Inc | Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos. |
| WO2023068382A2 (en) | 2021-10-20 | 2023-04-27 | Takeda Pharmaceutical Company Limited | Compositions targeting bcma and methods of use thereof |
| US20230390392A1 (en) * | 2022-03-07 | 2023-12-07 | Nkarta, Inc. | Multiplex gene edited cells for cd70-directed cancer immunotherapy |
| EP4507720A1 (en) | 2022-04-14 | 2025-02-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections |
| CN117100857B (zh) * | 2023-08-15 | 2024-09-10 | 福建医科大学附属协和医院 | 一种抗体金纳米笼载药系统、制备方法和用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228795A (en) * | 1977-03-08 | 1980-10-21 | Babington Robert S | Apparatus for producing finely divided liquid spray |
| WO1991016074A1 (en) * | 1990-04-19 | 1991-10-31 | Medimmune, Inc. | Administration of monoclonal antibodies against respiratory viruses |
| WO1992001473A1 (en) * | 1990-07-19 | 1992-02-06 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Improved immunotherapeutic method of preventing or treating viral respiratory tract disease |
| US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| US5833989A (en) | 1992-06-24 | 1998-11-10 | Adprotech Plc | Soluble CR1 derivatives |
| US5614370A (en) * | 1994-03-18 | 1997-03-25 | Merck & Co., Inc. | Assay to identify human C5a antagonists and agonists |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US20010036650A1 (en) * | 1994-08-16 | 2001-11-01 | Human Genome Sciences, Inc. | C5a receptor |
| EP0777474B1 (en) | 1994-09-23 | 2005-12-21 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of inflammatory joint disease |
| US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| CN1230178A (zh) * | 1996-09-10 | 1999-09-29 | 麦地诺克斯公司 | 含聚二硫代氨基甲酸酯的大分子和其用于治疗和诊断应用的用途 |
| JP2001503406A (ja) | 1996-10-28 | 2001-03-13 | ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ | 医薬組成物 |
| US7070799B1 (en) * | 1998-02-10 | 2006-07-04 | Generex Pharmaceuticals, Inc. | Method for administering insulin to the buccal region |
| US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| US20020182260A1 (en) * | 1998-05-29 | 2002-12-05 | Cellegy Pharmaceuticals, Inc. | Anti-inflammatory agents and methods for their preparation and use |
| US6093743A (en) * | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| WO2000006152A1 (en) * | 1998-07-30 | 2000-02-10 | Novopharm Biotech, Inc. | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
| US6280994B1 (en) * | 1998-11-25 | 2001-08-28 | Zymogenetics, Inc. | Zace 1: a human metalloenzyme |
| US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7109299B1 (en) * | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
| WO2001057025A1 (en) * | 2000-01-31 | 2001-08-09 | Pfizer Products Inc. | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| CA2399148A1 (en) * | 2000-02-10 | 2001-08-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| ATE435873T1 (de) * | 2000-03-23 | 2009-07-15 | Genentech Inc | Anti-c2/c2a inhibitoren zur komplement aktivierung |
| CA2405550A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| CA2413830A1 (en) * | 2000-06-21 | 2001-12-27 | Zymogenetics, Inc. | Peptide and polypeptide inhibitors of complement c1s |
| EP2386575A3 (en) * | 2000-06-29 | 2011-11-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| KR20030074693A (ko) * | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| US7795494B2 (en) * | 2001-03-22 | 2010-09-14 | Abbott Laboratories | Transgenic mice expressing antibodies specific for genes of interest and uses thereof |
| US8178098B2 (en) * | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| CN100343393C (zh) * | 2002-03-15 | 2007-10-17 | 布赖汉姆妇女医院 | 适合治疗剂全身性递送的中央气道给药 |
| US20040014782A1 (en) * | 2002-03-29 | 2004-01-22 | Krause James E. | Combination therapy for the treatment of diseases involving inflammatory components |
| CN101745112A (zh) | 2002-07-19 | 2010-06-23 | 艾博特生物技术有限公司 | TNFα相关疾病的治疗 |
| EP1545611B1 (en) * | 2002-09-06 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20030124139A1 (en) * | 2002-11-20 | 2003-07-03 | Irina Esikova | Compositions and methods for stabilizing biological molecules upon lyophilization |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| ZA200506159B (en) * | 2003-02-10 | 2006-10-25 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof |
| US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
| CN101600457B (zh) * | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
| JP4538514B2 (ja) | 2008-07-30 | 2010-09-08 | シャープ株式会社 | 画像圧縮方法、画像圧縮装置、画像形成装置、コンピュータプログラム及び記録媒体 |
| RS64039B1 (sr) | 2008-11-10 | 2023-04-28 | Alexion Pharma Inc | Metode i kompozicije za lečenje poremećaja povezanih sa komplementom |
| NZ613809A (en) | 2009-05-04 | 2015-02-27 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
-
2005
- 2005-05-11 US US11/127,438 patent/US20050271660A1/en not_active Abandoned
-
2006
- 2006-05-10 EP EP06759586A patent/EP1881993A2/en not_active Withdrawn
- 2006-05-10 JP JP2008511366A patent/JP2008540563A/ja not_active Withdrawn
- 2006-05-10 NZ NZ582627A patent/NZ582627A/en unknown
- 2006-05-10 WO PCT/US2006/018269 patent/WO2006122257A2/en not_active Ceased
- 2006-05-10 CA CA002608195A patent/CA2608195A1/en not_active Abandoned
- 2006-05-10 AU AU2006243994A patent/AU2006243994B2/en not_active Ceased
- 2006-05-10 NZ NZ563509A patent/NZ563509A/en not_active IP Right Cessation
-
2012
- 2012-09-04 JP JP2012193985A patent/JP2012233013A/ja active Pending
-
2014
- 2014-06-19 JP JP2014125985A patent/JP2014169332A/ja active Pending
-
2017
- 2017-08-11 US US15/675,074 patent/US10125191B2/en not_active Expired - Lifetime
-
2018
- 2018-10-04 US US16/152,235 patent/US10479828B2/en not_active Expired - Lifetime
-
2019
- 2019-10-09 US US16/597,040 patent/US10927166B2/en not_active Expired - Lifetime
-
2021
- 2021-01-19 US US17/152,054 patent/US20210214427A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540563A5 (enExample) | ||
| Newman | Principles of metered-dose inhaler design | |
| FAARC | Metered-dose inhalers, dry powder inhalers, and transitions | |
| JP2012528200A5 (enExample) | ||
| JP2012528792A5 (enExample) | ||
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| JP2007520508A5 (enExample) | ||
| RU2017144619A (ru) | Катионы одновалентных металлов сухих порошков для ингаляций | |
| HRP20220919T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne bolesti pluća | |
| JP5800829B2 (ja) | Ｃｏｐｄ用エアロゾル製剤 | |
| JP2007522229A5 (enExample) | ||
| JP2019517597A5 (enExample) | ||
| RU2006132036A (ru) | Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей | |
| HRP20050570A2 (en) | Powdered medicament for inhalation comprising a tiotropium salt and salmetrol xinafoate | |
| CN102186458A (zh) | 治疗慢性阻塞性肺病及其它肺疾病的方法 | |
| JP2005532988A5 (enExample) | ||
| JP2007528409A5 (enExample) | ||
| JP2007527430A5 (enExample) | ||
| CA2558426A1 (en) | Formulations decreasing particle exhalation | |
| JP2020023536A (ja) | Ｃｏｐｄの治療のためのフォルモテロール及びブデソニドの組み合わせ | |
| CN115768402A (zh) | 用于治疗急性肺损伤的5-氨基-2,3-二氢-1,4-酞嗪二酮 | |
| HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| Kaur | Pulmonary drug delivery system: Newer patents | |
| Dongare et al. | An overview of recently published patents on pulmonary drug delivery devices | |
| CN110799230B (zh) | 干燥粉末吸入器 |